Physician profile
Daniel B Meyer
NPI 1427412832
$3,268.00
in general payments reported to CMS, 2019-2025
30 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $480 · 2023: $600 · 2024: $1,109 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.81 |
| Education | $106.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $445.45 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $432.59 | 2021-2025 | Tavneos, Aranesp, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $366.72 | 2021-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $254.87 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $195.61 | 2024-2025 | |
| Travere Therapeutics, INC. | $170.67 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.11 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $113.94 | 2023-2024 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $106.97 | 2022-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.48 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $101.85 | 2023-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $85.85 | 2023-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $85.67 | 2021-2024 | Ultomiris |
| Genzyme Corporation | $66.15 | 2022-2023 | |
| Novo Nordisk INC | $63.40 | 2021-2023 | Ozempic, Rybelsus |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $56.82 | 2024-2025 | Onpattro, Oxlumo |
| Daiichi Sankyo INC. | $52.07 | 2021-2023 | Injectafer |
| Fresenius USA Marketing, INC. | $50.85 | 2022-2024 | |
| Scpharmaceuticals INC. | $42.47 | 2025 | |
| Horizon Therapeutics Plc | $37.89 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $37.80 | 2024 | Jardiance |
| Boston Scientific Corporation | $34.95 | 2025 | General - Therapies |
| Ardelyx, INC. | $33.69 | 2024 | Ibsrela |
| Vifor Pharma, INC. | $33.40 | 2022 | |
| Akebia Therapeutics INC | $32.93 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $22.32 | 2024 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $21.89 | 2025 | Empaveli |
| Actelion Pharmaceuticals US, INC. | $21.86 | 2025 | Opsumit |
| Leadiant Biosciences, INC. | $17.29 | 2022 | |
| Kyowa Kirin, INC. | $14.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.